Rofecoxib and tramadol do not attenuate delayed-onset muscle soreness or ischaemic pain in human volunteers

2005 ◽  
Vol 83 (12) ◽  
pp. 1137-1145 ◽  
Author(s):  
L.C. Loram ◽  
D. Mitchell ◽  
A. Fuller
Keyword(s):  
Muscle Soreness ◽  
Pressure Pain Threshold ◽  
Delayed Onset Muscle Soreness ◽  
Pain Tolerance ◽  
Mcgill Pain Questionnaire ◽  
Double Blind ◽  
Delayed Onset ◽  
Human Volunteers ◽  
Forearm Pain ◽  
Pain Rating Index

We assessed the effect of rofecoxib, a cyclo-oxygenase-2 inhibitor, and tramadol, a centrally acting analgesic, on both delayed-onset muscle soreness (DOMS) and experimentally induced ischaemic pain. We induced DOMS in 10 male and 5 female healthy volunteers by downhill running for 30 min at a 12% decline and a speed of 9 km·h–1. We also induced ischaemic pain by finger movements with an arterial tourniquet around the arm. In a randomized, double-blind crossover format, we administered rofecoxib (50 mg, daily), tramadol (50 mg, 3 times per day), and a placebo (orally for 3 days), starting immediately after exercise. A 100 mm visual analogue scale (VAS) and McGill pain questionnaire were used to describe muscle soreness and ischaemic forearm pain 24 h after the exercise. The pressure pain threshold (PPT) in the thigh and ischaemic pain tolerance in the forearm were measured before exercise and 24 and 72 h after exercise. PPT decreased 24 h after exercise, compared with pre-exercise values (ANOVA, p < 0.05), but neither drug had any significant effect on the PPT. Neither rofecoxib nor tramadol had any effect on time of ischaemia tolerated or amount of finger activity during ischaemia. The VAS and pain-rating index, for both muscle soreness and experimental ischaemic pain, were not affected significantly by either drug. Both DOMS and ischaemic pain share peripheral and central mechanisms, yet neither are attenuated by rofecoxib or tramadol.

scholarly journals Ultrasound v. sham ultrasound for experimentally induced delayed-onset muscle soreness: A double-blind, randomised controlled trial

2016 ◽  
Vol 26 (4) ◽  
Author(s):  
R Parker
Keyword(s):  
Analgesic Effect ◽  
Muscle Soreness ◽  
Controlled Trial ◽  
Specific Effect ◽  
Delayed Onset Muscle Soreness ◽  
Mcgill Pain Questionnaire ◽  
Double Blind ◽  
Delayed Onset ◽  
Clinical Benefits ◽  
Experimentally Induced

Background. Therapeutic ultrasound (US) is an electrophysical therapy that is commonly used by sports physiotherapists, but its mechanismof action is unclear. There is little evidence that US therapy is more effective than sham US therapy, and any clinical benefits may be dueto a placebo effect.Objective. To investigate whether US has a specific effect that renders it effective in its own right, or whether its effect is placebo driven.Methods. In a double-blind controlled trial, delayed-onset muscle soreness (DOMS) was experimentally induced in both bicep musclesof 15 females. Sham US was applied to one bicep (n=15 biceps) and pulsed active US to the other bicep (n=15 biceps) of each participant,48 and 72 h after induction of DOMS. Primary and secondary outcomes were pain reported on the McGill Pain Questionnaire (MPQ) andrange of movement (ROM) (elbow extension) measured by goniometry, respectively.Results. Results showed significant improvements in pain and ROM over the intervention periods, but there was no difference betweeninterventions.Conclusion. US and sham US therapy improve pain equally when treating DOMS of the biceps in the context of a therapeutic encounter.This analgesic effect is placebo driven. Clinicians can influence the analgesic effect of US by managing the therapeutic context. Managementof patients’ anxiety may also boost the analgesic effect of US.

scholarly journals The effectiveness of acupuncture for pain reduction in delayed-onset muscle soreness: a systematic review

2019 ◽  
Vol 38 (2) ◽  
pp. 63-74 ◽  
Author(s):  
Gloria Wing Yan Ko ◽  
Carl Clarkson
Keyword(s):  
Systematic Review ◽  
Muscle Soreness ◽  
Pain Threshold ◽  
Pressure Pain Threshold ◽  
Total Sample ◽  
Pain Reduction ◽  
Delayed Onset Muscle Soreness ◽  
Risk Of Bias ◽  
Eligibility Criteria ◽  
Delayed Onset

Objective: The aim of this study was to systematically review the literature on acupuncture for delayed-onset muscle soreness (DOMS) and report upon study quality and treatment outcomes. Design: Systematic review. Data sources: Searches were conducted in the following electronic databases from their inception to 31 March 2018: CINAHL, MEDLINE, Allied and Complementary Medicine (AMED) and SPORTDiscus. Reference lists of all included studies and relevant reviews were hand-searched for additional studies. Eligibility criteria for selecting studies: Randomised controlled trials (RCTs) that evaluated the effectiveness of acupuncture in DOMS in adults measuring the pre-specified primary outcome (pain) were included. Data collection and analysis: Data were extracted using pre-defined extraction forms and the Standards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA) checklist. Quality of studies was evaluated based on the Cochrane risk of bias assessment. Results: Five RCTs investigating laboratory-induced DOMS in the upper limbs with a total sample size of 182 healthy participants were included. Of the included studies, three reported superiority of acupuncture over no treatment in DOMS pain reduction as measured by visual analogue scale, pressure pain threshold or electrical pain threshold, while two studies yielded non-significant results. All studies demonstrated risk of bias in one or more areas, commonly lack of blinding of participants and personnel. Summary/conclusion: There is conflicting to limited evidence to support the effects of acupuncture on the relief of pain associated with DOMS. The findings were confounded by methodological limitations and reporting insufficiency. More rigorous, high-quality, and well-reported RCTs are required to further evaluate the effectiveness of acupuncture for DOMS.

Homoeopathic Arnica and Rhus toxicodendron for delayed onset muscle soreness

1997 ◽  
Vol 86 (01) ◽  
pp. 10-15 ◽  
Author(s):  
N. Jawara ◽  
G.T. Lewith ◽  
M.A. Mullee ◽  
C. Smith ◽  
A.J. Vickers
Keyword(s):  
Null Hypothesis ◽  
Muscle Soreness ◽  
Group Analysis ◽  
Delayed Onset Muscle Soreness ◽  
Controlled Study ◽  
Vigorous Exercise ◽  
Double Blind ◽  
Clinical Model ◽  
Delayed Onset ◽  
Stepping Exercise

AbstractWe intend to develop a simple, reproducible, clinical model to test the null hypothesis thatthe effects of ultramolecular homoeopathic preparations are always equivalent to placebo. A pilot of a randomized, double-blind, placebo-controlled study was conducted to assess the effects of Arnica and Rhus tox 30c on delayed onset muscle soreness. 50 healthy volunteers undertook a standard bench-stepping exercise, with outcome assessed using a validated soreness scale. Though the results of the trial favoured homoeopathy, differences between groups were small and did not reach statistical signficance (p>0.2). A sub-group analysis of subjects who did not take vigorous exercise and who would therefore be expected to be more responsive to treatment showed clinically but not statistically significant differences between groups (p>0.2). A second trial is currently under way in an attempt to replicate these findings.

Sign in / Sign up

Export Citation Format

Share Document